This study will assess the durability of protection of a single immunisation with the Genetically Attenuated Parasite 2 (GA2) against controlled human malaria infection by rechallenging previously immunised and protected participants from the CoGA study (NCT05468606)
Participant is aged ≥18 and ≤35 years and in good health.
Rechallenge group only: participation in CoGA study, having received immunisation with 1x 50 GA2-infected MB, and protected during subsequent CHMI.
Participant has adequate understanding of the procedures of the study and agrees to abide strictly thereby.
Participant is able to communicate well with the investigator.
For participants of child bearing potential: breastfeeding, or positive serum pregnancy test prior to CHMI.
Infection controls only: any history of malaria or previous participation in any malaria (vaccine) study or CHMI.
Known hypersensitivity to or contra-indications for both atovaquone/proguanil or artemether/lumefantrine. QT prolonging drugs are only considered an exclusion criterion when QT prolongation is observed at the ECG at screening.
A history of severe (allergic) reactions to mosquito bites.